Dr. Michael Alexander Joins Galaxy Therapeutics as Chief Medical Officer

Galaxy Therapeutics Welcomes Dr. Michael Alexander as CMO

Galaxy Therapeutics, a private clinical-stage medical device company, has recently announced the appointment of Dr. Michael Alexander as its new Chief Medical Officer (CMO). This transition marks a significant milestone for the company, which is dedicated to advancing therapies for brain aneurysms. Dr. Alexander's extensive experience and expertise in the neurosurgery field align perfectly with Galaxy's mission, as they continue progressing towards the commercialization of their SEAL™ device.

A Leader in Neurosurgery

Dr. Michael Alexander is a highly esteemed professional in the neurovascular sector, bringing over two decades of rich experience to his new role. He has been profoundly involved in clinical research and patient care, highlighting his dual training as both a cerebrovascular neurosurgeon and a neurointerventionalist. Under his leadership, the Cedars-Sinai Medical Center in Los Angeles flourished, where he served in various high-profile positions, including Professor, Vice Chair of Neurosurgery, and Co-Director of the Comprehensive Stroke Center. His collaborative role with the Los Angeles Rams as Team Neurosurgeon during the 2016-2017 season stands testament to his stellar reputation in the industry.

Contribution to Clinical Initiatives

In his capacity as CMO at Galaxy Therapeutics, Dr. Alexander is set to oversee the global medical direction across all clinical development programs. This includes the ongoing Saccular Endovascular Aneurysm Lattice (SEAL™) IDE trial and future endeavors targeting complex brain aneurysms. His involvement is expected to streamline the progression towards the development and regulatory approval of this innovative device.

Dr. Sam Zaidat, President and CEO of Galaxy Therapeutics, expressed enthusiasm regarding Dr. Alexander's appointment, underscoring his extensive experience with clinical trials and significant contributions to neurointerventional research. Zaidat noted, “We are honored to welcome him and are confident he will be pivotal in bringing our technology to patients globally.”

Experience and Accomplishments

Dr. Alexander's impressive career is marked by participation in over 45 clinical trials, with a continuous funding record from the National Institutes of Health (NIH) that stretches beyond 18 years. He has also served as the Past President of the Society of NeuroInterventional Surgery (SNIS), co-authored two textbooks, and published over 160 peer-reviewed articles focusing on neurovascular diseases. His academic credentials include an M.D. from Georgetown University School of Medicine, alongside fellowships in Neurovascular and Skull Base Surgery and NeuroIntervention from leading institutions such as Barrow Neurological Institute and UCLA.

The Future of Galaxy Therapeutics

Founded by four practicing neurointerventional doctors, Galaxy Therapeutics is committed to innovating solutions for brain aneurysm treatment. With headquarters in Milpitas, California, the company maintains a focus on developing novel implant technologies and has secured multiple patents internationally. As Dr. Alexander takes on his new role, he will continue to manage his academic and clinical responsibilities while contributing to Galaxy’s strategic objectives. This dual approach aims to further enhance the company’s clinical and scientific endeavors as they seek to redefine brain aneurysm treatments through their proprietary SEAL device.

In conclusion, the addition of Dr. Michael Alexander not only enriches Galaxy Therapeutics' leadership team but also fortifies its commitment to bringing breakthrough solutions to patients suffering from neurological challenges. With his profound knowledge and understanding of neurointerventional techniques, Dr. Alexander's role is anticipated to be a significant catalyst for the company’s growth and innovation in the medical device landscape.